Business · 17/11/20261 min read
Five-year data of continuous Leqembi® treatment show increasing benefit over time
Summary
STOCKHOLM, Nov. 17, 2026 — BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today presented new five-year data from the Clarity AD study and its long-term extension, showing increasing clinical benefit with continuous Leqembi treatment in early Alzheimer's...